Bloomberg Audio Studios, podcasts, radio news Time Now for some top calls.
The analyst actions that we are following. First up, Jeffries cuts Deer to a Cell, saying the stock already reflects a.
Full recovery and farm demand.
The firm also warned that higher costs, trade uncertainty, and heavy debt could hamper the company's recovery. Next up, well as Fargo, they upgrade Alphabet Dubui, calling it an AI winner with strengths and consumer data distribution and compute capacity. Shares only up two tens and percent, And finally, Bank of America downgrades General Mills, saying its recovery story is not playing out.
The firm says hopes for a PET rebound.
Instead, her sales have stalled as shoppers pull back elsewhere. Nover Noordous next Generation OPEC shot cagri Semma underperformed Eli Lilly's to Zeppra Tide and a head to head trial. Let's bring a nover Noordous Chief Scientific Scientific Officer Mark and host Long on this. Martin, thank you so much for joining us this morning. And I just want to bring you a comment from a shareholder of nov Nordice of global Health invest NOV notice this opportunity to make a comeback in the.
Fight against Lily. This was it.
This obviously weekends them in a fight. What would be your message to those who believe the same thing, who have looked at this study and said, now this means NOVO is falling even further behind Eli Lilly, I.
Would answer, it's been a few years since we designed the redefined program, the program to show the weight loss potential of caguisemma. We already last year learned that to really see the true weight loss potential of cagurosemma, it is a very powerful combination of two molecules. We need to have what we call it this both titration algorithms to really allow patients to tyitrate the very powerful treatment
in the way that they prefer. We could see from the first study that that could be further optimized in this setting. We could not manage to implement those learnings in what we call redefined form, which is the study that we discussed today, So the jury is still out
of what can caguissemma actually achieve. In the study that read out today, we saw twenty three percent weight loss with cagrissimma that is actually very substantial and it is among the best weight losses that we've seen also amongst the drugs in the market.
Right, of course, just sort of the shore point in that if I can jump in Martin is just the comparison to Lily, it will forever be there.
So what is the plan then to catch up with them?
Yeah, exactly. So, first of all, the twenty three percent weight loss that we solved with cagris emma is in line with what we've previously seen. The twenty five percent which we saw with the comparative drug is actually the best data that has been seen so far in similar trials, which is a little bit surprised, but it stands alone in terms of that twenty five percent. But we've also taken a lot of learnings in terms of how we
can improve the titration for cagrisemma. We've implemented those learnings in the study that's currently ongoing that started it is called Redefine eleven and reguarded for the last year. That only when we see those data do we know the full weight loss potential of cagrosemma. Furthermore, we are initiating during this year Phase three start is to investigate it
even higher doses of cagrisemma. And then obviously we have our very competitive pipeline starting within agamside that starts phase three this year, but also our two triagonist that is currently in phases one and two. So I think from a short but also a longer term perspective, we have a very competitive portfolio and pipeline.
Martin, on that pipeline, you seem confident on it. You would you like to see that bolstered by some m and a by bringing in organic growth to the pipe line too.
The way we think about this is that business is a very complex disease, and obviously we want to have drugs that provide the biggest weight loss, but we also have want to have drugs that gives as few side effects as possible. That we also have want to have drugs that provide commobidities, and to an extent, in our
current portfolio we have all of that. We also have the best in class all already on the market in the US, and the Senate Game Site offering that is starting phase three will have both a subconchaneous and an awful all offering with what we be with market.
Why why within that did you not follow Lily with the truer Zepra tide and develop a g LP one g I P Why not go down that route when so many other companies did.
We need to follow our philosophy. Where we do development, we also want to we always want to see differentiated weight loss potential or efficacy potential, but also the differentiated safety and sol ability. We do believe that we will see that when we see redefine eleven in terms of weight loss CAKU SMA. But we also believe that we have that potential for EMI cretin, which is another version of addressing two biologies. So you mentioned GLP one g
ip senagamtide is GLP one plus sorry, Emlin. And then we have what we call triagonist, which is basically the next level.
We do again.
Believe that that is going to be a very competitive offering individually but specifically as a portfolio.
Okay, Martin, we're going to have to leave it there. Thank you so much for joining us today. That's never not As Chief Scientificate Officer, Martin host Long